PATENT CLAIM ANALYSIS

Application Number: 16280356
Application Type: Utility
Filing Date: 2019-02
Publication Date: 2019-06
Patent Classification: ["424", "278100"]

Abstract:
The present invention provides formulations that support an individual's body during routine vaccination and adaptive immune response. The individuals who can benefit from these formulations are infants, children and adults. The formulations comprise ingredients that can be administered prior to, concurrent with or subsequent to the vaccination. The formulations of the present invention preferably act by targeting enzymatic reactions an individual's various metabolic pathways, maintaining balance between oxidative stress and methylation, maintaining balance between Th1 and Th2 responses, or a combination thereof during vaccination and adaptive immune response.

Claim (Index 1):
A method of supporting the healthy state of an individual's body in conjunction with receipt of vaccinations and during adaptive immune responses which target epigenetic regulation of gene expression, specific enzymatic reactions, cytokine differentiation, immune system homeostasis and proper functioning of various metabolic pathways thereby improving antibody response and decreasing vaccine side effects by positively affecting the balance between oxidative stress, methylation, transsulfuration and maintaining the balance between TH1 and Th2 response, comprising:\n administering a pharmacologically acceptable amount, to an individual, of the following formulation: 1 mg -10 mg of thiamin (Vitamin B1), 0.1 mg-500 mg of riboflavin (Vitamin B2) 0.5 mg-1 g of niacin (Vitamin B3), 0.5 mg-10 mg of pantothenic acid (Vitamin B5), 0.1 mg-25 mg of pyridoxine (Vitamin B6), 5 mcg-1 mg of folate (vitamin 139), 10 mcg-5,000 mcg of cobalamin (Vitamin B12), 10 mcg-1,000 mcg of Vitamin A, 50 IU-1,000 IU of Vitamin D, 1 mg-20 mg of Vitamin E, 5 mg-5,000 mg of Vitamin C, 0,5 mcg-300 mcg, of Vitamin K, 50 mg-800 mg of Calcium, 20 mcg-15 mg of Iodine, 5 mg-200 mg of Magnesium, 1 mg-15 mg of Zinc, 5 mcg-200 mcg of Selenium, 0.1 mg-5 mg of Manganese, 1 mcg-150 mcg of chromium, 1 mcg-100 mcg of molybdenum, 10 mg-1 g of trimethylglycine (betaine), 10 mg-1 g of choline, 50 mg-2 g of acetyl-L-carnitine, 20 mg-500 mg of N-acetyl cysteine, 50 mg-800 mg, of milk thistle and 20 mg-800 mg of creatinine or a combination thereof; administering said formulation prior to the administration of a vaccine, concurrent with the administration of a vaccine or subsequent to the administration of a vaccine; and administrating said formulation to said individual where the individual is an infant, a toddler, a teenager or an adult.

Metadata:
- Claim Count in Document: 20.0
- Percentile: 99.0
- Lexical Diversity: 1.57143
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15226415', '14662143', '12080189', '12157077', '11943176']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7154356415719747
- 35 USC 102 Novelty (BERT): 0.5463451246747414
- Combined Prediction Score: 0.6985265898822515
- Mean Citation Score: 254.194662
- Max Citation Score: 440.54672
- Similarity Product: 252.71547815670013

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test